ALK: Starting in 2026, research and development investment will focus more on innovative drug projects

Zhitong
2025.10.30 03:15

On October 29th, ALK stated during an institutional research that after 2-3 years of high-intensity R&D investment, the generic drug projects planned by the company have gradually entered the output stage. Starting in 2026, the R&D investment related to generic drugs is expected to gradually decrease, with more focus on innovative drug projects

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer